Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphorylase, glycogen | Starlite/ChEMBL | References |
Mus musculus | liver glycogen phosphorylase | Starlite/ChEMBL | References |
Rattus norvegicus | Liver glycogen phosphorylase | Starlite/ChEMBL | References |
Homo sapiens | phosphorylase, glycogen, liver | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0522 | 0.5 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.0522 | 0.5 | 0.5 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.0522 | 0.5 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0522 | 0.5 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0522 | 0.5 | 0.5 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.0522 | 0.5 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Giardia lamblia | Glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0522 | 0.5 | 0.5 |
Chlamydia trachomatis | glycogen phosphorylase | 0.0522 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Cmax (ADMET) | = 44 nM | Plasma clearance of the compound was determined in male mice after i.v. administration at a dose 1 mg/kg | Starlite. | 14592521 |
Cmax (ADMET) | = 44 nM | Plasma clearance of the compound was determined in male mice after oral administration at a dose 2 mg/kg | ChEMBL. | 14592521 |
Cmax (ADMET) | = 44 nM | Plasma clearance of the compound was determined in male mice after oral administration at a dose 2 mg/kg | ChEMBL. | 14592521 |
F (ADMET) | = 4.1 % | Oral bioavailability of the compound was determined in male mice after i.v. administration at a dose 1 mg/kg | ChEMBL. | 14592521 |
F (ADMET) | = 4.1 % | Oral bioavailability of the compound was determined in male mice after i.v. administration at a dose 2 mg/kg | Starlite. | 14592521 |
F (ADMET) | = 4.1 % | Oral bioavailability of the compound was determined in male mice after i.v. administration at a dose 1 mg/kg | ChEMBL. | 14592521 |
IC50 (binding) | < 9 nM | Inhibitory activity against mouse liver glycogen phosphorylase | ChEMBL. | 14592521 |
IC50 (binding) | < 9 nM | Inhibitory activity against rat liver glycogen phosphorylase | ChEMBL. | 14592521 |
IC50 (binding) | < 9 nM | Inhibitory activity against mouse liver glycogen phosphorylase | ChEMBL. | 14592521 |
IC50 (binding) | < 9 nM | Inhibitory activity against rat liver glycogen phosphorylase | ChEMBL. | 14592521 |
IC50 (binding) | = 10 nM | Inhibitory activity against HLGP(human liver glycogen phosphorylase) | ChEMBL. | 14592521 |
IC50 (binding) | = 10 nM | Inhibitory activity against HLGP(human liver glycogen phosphorylase) | ChEMBL. | 14592521 |
IC50 (binding) | = 60 nM | Inhibitory activity against HMGP(human muscle glycogen phosphorylase) | ChEMBL. | 14592521 |
IC50 (binding) | = 60 nM | Inhibitory activity against HMGP(human muscle glycogen phosphorylase) | ChEMBL. | 14592521 |
Ratio (binding) | = 6 | Ratio of HMGP to that of HLGP was determined | ChEMBL. | 14592521 |
Ratio (binding) | = 6 | Ratio of HMGP to that of HLGP was determined | ChEMBL. | 14592521 |
T1/2 (ADMET) | = 60 min | Half life of the compound was determined in male mice after i.v. administration at a dose 1 mg/kg | ChEMBL. | 14592521 |
T1/2 (ADMET) | = 60 min | Half life of the compound was determined in male mice after oral administration at a dose 2 mg/kg | Starlite. | 14592521 |
T1/2 (ADMET) | = 60 min | Half life of the compound was determined in male mice after i.v. administration at a dose 1 mg/kg | ChEMBL. | 14592521 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.